To explore differences in mechanisms of carcinogenicity at low and high exposures, we have conducted a series of exposureresponse studies of hepatocarcinogenesis in rats using 2 well-studied DNA-reactive carcinogens, 2-acetylaminofluorene and diethylnitrosamine. In these studies, we have used intraperitoneal injection or intragastric instillation to deliver exact doses during an initiation segment followed by phenobarbital as a liver tumor promoter to enhance manifestation of initiation. This protocol results in carcinogenicity comparable to that produced by lifetime exposure to the carcinogens. Our findings in these experiments provide evidence for the following: (a) formation of DNA adducts can be nonlinear, with a plateau at higher exposures; (b) cytotoxicity shows no-effect levels and is related to exposure; (c) compensatory hepatocyte proliferation shows no-effect levels and can be supralinear at high exposures; (d) formation of preneoplastic hepatocellular altered foci can show no-effect levels and appears supralinear at high exposures; (e) no-effect levels can exist for tumor development, and the exposure response can be supralinear. We interpret these findings to reflect thresholds for hepatocellular initiating effects of these carcinogens and exaggerated responses at high exposures attributable to cytotoxicity and compensatory hepatocyte proliferation. Such enhanced proliferation of hepatocytes harboring DNA damage likely results in an exaggerated yield of mutations in critical genes, leading to supralinear initiation of carcinogenesis. Thus, mechanisms differ between low and high exposures. Based on these observations, we suggest that linear extrapolation from high toxic exposures to postulated low-exposure effects of DNA-reactive carcinogens can yield overestimates. Such extrapolation must be supported by mechanistic information. The finding of no-effect levels provides a basis for understanding why low-level environmental exposures of humans to even DNA-reactive carcinogens may convey no cancer risk.
INTRODUCTION
The purpose of animal carcinogenicity bioassays is to identify potential human cancer hazards. In the interpretation of findings, the default position is that any evidence of carcinogenic activity can be extrapolated to humans, unless scientific information proves otherwise (45, 55) . It is now recognized that certain carcinogenic effects, such as the induction of male rat kidney tumors by agents that produce a2w-globulin (10, 29, 43) , are species specific.
Also, some agents lead to cancer development only at doses that produce cytotoxic effects that do not occur at lower doses (45) : for example, butylated hydroxyanisole (42) . For agents with these characteristics that are also nongenotoxic, regulatory agencies will allow use of a margin of exposure in risk assessment (25, 57) . Implicit in such an approach is the idea that carcinogens of this type have thresholds.
The principle of thresholds was originally demonstrated in physiology and pharmacology, in which various cellular responses have been demonstrated to require a specific number or concentration of effectors in order to evoke a response. Today, every field of biomedicine (including toxicology) recognizes the existence of thresholds. For example, in humans, alcoholic liver toxicity occurs only with high-level intake; millions of moderate consumers experience no liver injury with low-level intake. Similarly, the carcinogenic activity of nongenotoxic or epigenetic carcinogens is dependent upon exceeding the threshold for the cellular effect that underlies carcinogenicity (3, 54, 55) . This is a true toxicologic threshold in the same sense as is indicated in physiologic or pharmacologic thresholds.
The issue is more controversial for carcinogenic agents that are DNA reactive. These are the archetypal carcinogens for which &dquo;one hit, no threshold&dquo; concepts were introduced; this concept led to the development of linear extrapolation models (21, 57) . Although possible under certain circumstances, the realistic potential for such a mechanism can be questioned (2) . To begin with, cancer is a progressive disease, in which somatic cells undergo a series of genetic alterations which culminate in a neoplasm that exhibits multiple gene defects in those genes controlling cell proliferation, cell behavior, and genomic stability (ie, oncogenes, tumor suppressor genes) (4, 17, 48) . The chemical induction of such defects would require a substantial number of DNA interactions in order to produce the spectrum of critical changes. The mutations present in tumor cells, of course, also reflect the selection of those cells from among many others that probably harbor mutations that do not provide a growth advantage. That is, for every critical mutation, there may be many more mutations that do not lead to tumor development. Multiple mutations could arise from a mutation in a mutator gene (18), but even these genes are represented by multiple copies, and loss of function probably requires more than one mutation. Furthermore, high exposures with multiple hits may be required to produce certain changes. The pattern of DNA adducts differs with dose (32) , which perhaps accounts for the fact that mutagenesis (40, 41) and oncogene activation (1, 19) are qualitatively different at high and low exposures. The extent and persistence of DNA adducts in specific tissues does not correlate with their tumor response (23) , which indicates the existence of no-effect levels (NELs) for DNA damage in some tissues. A particularly compelling example of this is provided by the EDo, study of 2-acetylaminofluorene (AAF) in mice, a study that revealed an apparent NEL for urinary bladder neoplasms (6, 7) , although in this study and in a major study on diethylnitrosamine (DEN) in rats (26, 27) , the exposure response for liver neoplasms was considered to be linear, with no NEL.
An international expert panel (16) conducted a review in 1996 of cancer mechanisms and a risk assessment that included comprehensive reviews of DEN (36) and AAF (35) carcinogenicity as well as reviews of other DNAreactive and epigenetic carcinogens. The panel noted that for most DNA-reactive carcinogens, protective mechanisms at low doses have not been clearly identified but that detoxification or DNA repair could modify the doseresponse relationship at low doses.
To explore differences in the action of DNA-reactive carcinogens at high and low exposures, we have conducted a series of exposure-response studies of hepatocarcinogenesis in rats using AAF and DEN. These experiments are characterized by several features. First, they involve precise dose administration by subcutaneous or intraperitoneal (IP) injections or intragastric (IG) administration. Also, they utilize an initiation/promotion (II P) protocol, which, as discussed at the end of this paper, provides results comparable to those obtained with chronic administration. Finally, the studies were conducted in Fischer 344 (F344) male rats, which are highly sensitive to these carcinogens (35, 36) .
The paradigm on which we have based our investigations is shown in Figure 1 . Our hypothesis is that NELs exist for each essential step in the process, which, combined with a NEL for tumors, would support the existence of thresholds for cellular responses to DNA-reactive carcinogens.
MATERIALS AND METHODS
In all studies, male F344 rats of about 8-12 weeks of age were used. High-purity AAF (>99%) or DEN (>99%) was administered either by IP injection or by IG instillation to achieve precise mole-per-kilgram body weight doses in initiation segments (ISs). In the DEN experiments, dosing was once weekly, whereas in the AAF experiments, dosing was daily. In experiments in which neoplasms were quantified, phenobarbital (PB) at 0.05 or 0.06% (in the diet) was used as the promoting stimulus in promotion segments (PSs). In some studies, a recovery segment (RS) was allowed between IS and PS. Animals were maintained (6 of them) in solid-bottom cages with hardwood chip bedding in temperature-, hu- midity-, and light cycle-controlled rooms in an accredited facility. All experiments were approved by an institutional review committee and conformed to national guidelines.
Measurement of DNA adducts formed by AAF was accomplished using radioimmunoassay or the 32P-postlabeling method. For DEN adducts, high-performance liquid chromatography with fluorescence detection was used to quantify N7-ethylguanine or 06-ethylguanine. To measure the persistent and accumulating 04-ethylthymidine DNA adduct, an immunoslot blot assay was used. To assess toxicity, reduction of glutamine synthetase-positive (GS+) centrilobular hepatocytes was quantified by immunohistochemistry and expressed as the relative mean width, which is the ratio of the GS+ area to the perimeter of the venule in micrograms (9) . Cell proliferation was monitored through immunohistochemical staining of bromodeoxyuridine incorporation or proliferating cell nuclear antigen (PCNA). Standard sections were taken from each lobe of the liver for routine (H&E) histopathological examination, and preneoplastic hepatocellular altered foci (HAF) were quantified by several markers, including the placental form of glutathione S-transferase (GST-P) enzyme, using a microscope equipped with a drawing attachment and an electronic visual digitizing system.
RESULTS

Exposure-Response Investigations of DEN
To assess the exposure response for early effects and neoplastic transformation induced in rat liver by limited exposures to DEN, the carcinogen was given weekly for 10 weeks in an IS followed by further study for 24 weeks in a PS to manifest initiation (47) . In the IS, 3 cumulative exposures of 1 (low exposure; LE), 2 (mid exposure; ME), or 4 (high exposure: HE) mmol/kg body weight were achieved by weekly or biweekly injections for 10 weeks. In the PS, the rats were maintained on basal or PB-containing diets. Early effects relevant to initiation, including formation of preneoplastic lesions, were quantified in the IS. Preneoplastic and neoplastic lesions were TABLE Summary of exposure-response effects of diethylnitrosamine in experiment 1 in male rat liver.&dquo;
Abbreviations: C = control; LE = low exposure; ME = mid-exposure; HE = high exposure.
&dquo; Williams et al (1993). 6 Total mmol/kg body weight. < RMW value of the GS+ area at 10 weeks. dGGT' HAF per cm2 of liver section at 10 weeks. e Percent incidence of liver neoplasms at 34 weeks. quantified in the PS. At the end of the IS, DEN had produced an exposure-related decrease in centrilobular GS-expressing hepatocytes (Table 1 ), as previously described (8) , which is indicative of cellular toxicity (9) although there was no overt cell injury in H&E microscopy. All exposures induced HAF that were ~y-glutamyltranspeptidase-positive and iron storage-deficient. The multiplicity of foci in the ME exceeded that in the LE by about a factor of 3.5, and in the HE, the multiplicity of foci was > 100-fold greater, which documented supralinearity. With maintenance for 24 weeks after exposure, there was a reduction in the numbers of HAF, as we have described in other experiments (53) . At 34 weeks, neoplasms were present in the ME and HE groups. Administration of PB after DEN increased the multiplicity of foci in all exposure groups, most substantially in the HE group. The effect of PB on liver neoplasm yield was marginal with the noncarcinogenic LE, whereas it enhanced the multiplicity in the weakly carcinogenic ME by -6-fold. Four principal observations were made: (a) even at the low doses used, a mild cytotoxicity was manifested in the GS+ centrilobular subpopulation of hepatocytes, which was not evidenced by morphological changes in conventional histopathology;
(b) the dose response was nonlinear over a 4-fold dose range of DEN alone and when followed by PB; (c) the precursor role of foci in the evolution of liver neoplasms was evident; and (d) a substantial induction of foci was required for the evolution of neoplasms, even with PB promotion.
In a subsequent experiment (49) , a similar exposureresponse investigation for several effects of limited exposures to DEN in the livers of rats was conducted. In the IS, 5 exposures-ranging from a cumulative total of 0.5 (LE) to 1.0 (mid-low exposure; MLE) to 2.0 (ME) to oped hepatocellular carcinomas. These findings document nonlinearity for some of the effects of DEN and a near NEL for initiation of promotable liver neoplasms at the LE, in spite of a substantial induction of HAE Finally, as in the previous study, PB clearly enhanced development of preneoplastic and neoplastic lesions, as expected (39) . Accordingly, in subsequent studies in the PS, only groups given PB were included.
To extend these investigations, in a third experiment (48) , 4 exposures-involving cumulative exposures of 0.25 (LE) (which is one-half of the previously used LE), 0.5 (MLE), 1.0 (MHE), and 2.0 mmol (HE) DEN/kg body weight-were studied. In the IS, these exposures were achieved by once-a-week IG instillations of 1/lOth the cumulative exposures for 10 weeks. The IS was followed by a 4-week RS, after which the groups were maintained on 0.06% PB in the diet for 24 weeks in a PS. The LE produced a low level of DNA ethylation at both 5 and 10 weeks of exposure, measured as 04-ethylthymidine, the most persistent ethylation product (Table   3 ). At the 5-week interval, the adduct values of the MHE and HE were not proportional to the increment of exposure, which was suggestive of nonlinearity. Assessment of hepatocellular proliferation by staining for PCNA revealed that the LE did not increase cell replication during administration (10 weeks) or recovery (4 weeks), whereas in the 3 higher exposure groups, increased hepatocellular proliferation was dose and time proportional. Preneoplastic HAF expressing GST-P were present at low multiplicity in control livers and were increased in the MLE group by week 10, and in the MHE and HE groups, increases were already evident at 5 weeks. At the end of recovery, HAF multiplicity was increased in all exposed groups, and the HE group was disproportionately greater than the increment of exposure. At the end of the RS, HAF were further increased in all groups compared to the multiplicities at the end of IS, except for the HE.
After PB administration in the PS, all exposure groups exhibited further HAF increases at 39 weeks. At the end of the PS, no hepatocellular neoplasm was found in controls or in the LE group. In the MLE group, which was the previously studied LE, only 1 adenoma was found, whereas the incidence of liver neoplasms was 32% in the MHE and 80% in the HE, increases that were dispropor- tionately greater than the increments of exposure. These findings confirm previously documented nonlinearities of early DEN effects and, at the lowest cumulative exposure, a possible NEL or threshold for initiation of promotable liver neoplasms.
Exposure-Response Investigations of AAF
In an initial study (34) , we measured the effect of precise exposures to AAF in terms of their ability to produce effects in rat liver (as studied for DEN). Doses yielding a cumulative LE of 0.5 or a HE of 2.0 mmol AAF/kg body weight were achieved by daily IG administration for 5 days per week over an 8-week period. Exposure to AAF resulted in the formation of N-deoxyguanosine-(8yl)-2-aminofluorene in liver DNA in relationship to exposure (Table 4 ), although the amount increased disproportionately to exposure. Indicative of cytotoxicity of AAF, as previously reported (8) , the area of GS-expressing hepatocytes in the centrilobular zone was reduced by about 40% at 4 weeks at both exposure levels, and at 8 weeks, the LE recovered, but inhibition by the HE increased to about 60%. By 8 weeks (but not at 4 weeks), the HE provoked a compensatory increase in hepatocellular proliferation as measured by immunohistochemical incorporation of bromodeoxyuridine. Hepatocellular altered foci expressing GST-P were induced by the HE at 4 weeks but not by the LE. At 8 weeks, the incidence of foci at the HE was 79 times that induced by the LE. These foci were highly proliferative. In animals exposed to AAF for 8 weeks and maintained for 4 weeks with no exposure, DNA adducts decreased by 80%, (data not shown), reflecting DNA repair, and cell proliferation subsided by 80%, although the GS zone remained diminished. After discontinuation of AAF, the number of foci diminished by 50%, and their proliferation subsided by 80% at 4 weeks, indicating a phenotypic reversion of many foci, as described above for DEN-induced HAF and as previously reported (53) . These findings thus demonstrate that in this protocol of administration of precise doses of AAF, nonlinearity of effects was observed, as was the case for DEN. Moreover, there was lack of correlation between DNA adduct formation and induction of cellular lesions.
In a follow-up study (50) . the exposure responses for several effects of low-level exposures to AAF were mea- produced adducts in liver DNA, as measured by 32P postlabeling, and the level of adducts increased with exposure, except that the HE did not produce an increase that was proportional to exposure ( Table 5 ). Aryl sulfotransferase, the enzyme involved in the formation of the reactive sulfate ester of AAF (20) , is known to be inhibited by cytotoxic levels of AAF (28) . In livers from the ME and HE animals, the enzyme was inhibited, but this was not the case with LE. Further indicative of cytotoxicity, the centrilobular zone of GS+ hepatocytes was reduced in the HE group, and there was a trend toward reduction in relationship to exposure. The 2 lower exposures to AAF produced no increase in compensatory hepatocellular proliferation, whereas the HE resulted in a marked increase of about 8-fold over controls by 12 weeks. Initiation assessed by induction of HAF that expressed GST-P was induced in the HE group, the multiplicity of HAF being increased 176-fold at 12 weeks, compared with controls. In the PS, in rats maintained on PB for 24 weeks after the IS, the multiplicity of HAF increased in controls and increased comparably in the LE and ME groups, but it remained at about the same level in the HE group. The HE produced a 50% incidence of benign neoplasms by 12 weeks, and with promotion by 36 weeks, all rats developed hepatocellular neoplasia. In the ME group, only 1 adenoma occurred at 36 weeks in 17 rats, whereas in the LE group, no liver tumors occurred in 23 rats. These findings document nonlinearities for some of the effects of AAF, with supralinear effects at the HE for cell proliferation and induction of HAF and a no-observed-effect level for induction of promotable liver neoplasms at the LE of 0.126 mmol/kg, in spite of the formation of DNA adducts. We conclude that this experiment has shown that the effects of AAF that lead to initiation exhibit nonlinearities and possible thresholds.
DISCUSSION
We have conducted a series of exposure-response investigations with 2 DNA-reactive hepatocarcinogens to characterize differences in effects at high and low exposures and to attempt to delineate thresholds for cellular responses. These experiments involved precise dosimetry and were highly reproducible. Although the focus of these studies was the initiation of hepatocarcinogenesis by limited exposures in an I/P protocol, the use of PB as a promoting agent in fact produced neoplastic responses that were comparable to those found by others who used chronic administration (Table 6 ). Specifically, our most recent VP study can be compared with the major DEN dose-response study of Peto et al (26, 27) , in which rats were dosed with DEN in the drinking water, starting at 6 weeks of age, over a 512-fold concentration range from 0.033 to 16.896 ppm; this dosing regimen was continued for the lifetime of the rats. The authors considered that over the observable range, the response was linear, although the 4 lowest doses tested showed no hepatocellular tumors, whereas in the control group, there was 1 tumor in a group of 60 rats. In contrast to this study, in the I/P protocol, we dosed with DEN weekly for only 10 weeks, followed by 4 weeks of recovery and then 24 weeks of promotion with PB. Our highest cumulative dose of 2 mmol/kg yielded an 80% hepatocellular tumor incidence and best corresponds to the effect of the highest dose used by Peto et al (16.896 ppm) , which we calculate to yield a 10 mmol/kg cumulative dose (Table 6 ). With this exposure, Peto et al obtained a result in which 78% of the animals displayed hepatocellular tumors. We calculate that on a daily basis, we gave 2.6 times the amount of DEN, but cumulatively, we gave only 0.20 times the total exposure, and we obtained a comparable tumor yield. At equivalent daily exposures, Peto et al obtained 47% tumors with 6.3 ppm in approximately twice the exposure time. Likewise, comparing of the carcinogenicity of AAF in an I/P protocol with a cumulative dose of 1.26 mmov kg to that in a chronic oral study of 76 weeks' duration with a cumulative dose of 7.9 mmol/kg (52) showed that both protocols produced a 100% tumor incidence. In the latter study, at an interim sacrifice at 48 weeks (at which the cumulative dose is calculated to be 5.0 mmol/ kg, which is about 4 times the exposure in the VP protocol), only 25% of the animals had liver adenomas, but none had carcinomas. Thus, using our model of initiation and promotion, it appears that tumors can be developed earlier and at lower cumulative exposures to the initiating agent. Therefore, although we are quantifying initiation and promotable neoplasia, the results are equivalent to those produced by certain lifetime exposures ( Table 6 ).
All the exposures that we studied for AAF or DEN were shown to produce adducts. Nevertheless, the lowest of these exposures were minimal or noninitiating exposures. Accordingly, we speculate that lower exposures, particularly those that do not induce foci, and exposures that do not produce measurable DNA adducts would be below a threshold for carcinogenesis.
At the high end of the exposure ranges that we studied, which were still below those used by others for AAF (23) or DEN (26, 27) , we found that the carcinogens were producing hepatotoxicity, which was not apparent in conventional histopathological slides but which could be documented by inhibition of hepatocellular enzymes (ie, GS and arylsulfotransferase). This cytotoxicity led to compensatory hepatocellular proliferation. At such exposures, there was a supralinear induction of HAF and possibly even eventual tumor yield. We suggest that this is a consequence of carcinogen DNA adducts being converted to mutations at a high frequency because of enhanced cell proliferation and consequent reduced opportunity for repair, as detailed in liver cell culture (33) . Thus, at high doses, AAF and DEN exert dual effects that underlie cancer risk (2) , as has also been described for formaldehyde (32) .
These studies provide further support for the role of HAF as precursors of hepatocellular neoplasms (44) . As shown in other studies (13) , HAF are heterogeneous. In the present series of experiments, in which RSs were allowed, some HAF characterized by -y-glutamyltransferase activity or iron storage deficiency underwent phenotypic reversion, as previously described (53) . In one of our experiments using AAF (34), GST-P+ HAF showed evidence of reversibility, but in another with DEN (48), no reversibility was observed. The GST-P phenotype of HAF induced by some agents and, in particular, the GS phenotype (8) , thus appears to be more stable than some other phenotypic alterations. Regardless, the fraction of HAF that is susceptible to promotion to neoplasms is extremely low-less than 1 in 1,000 (39) . In the present studies, this is reflected by the fact that exposures that induced small multiplicities of HAF were not associated (5, 12, 30) , would probably be below a carcinogenic threshold.
Collectively, then, our findings with DEN and AAF document the following (Table 7) : (a) formation of adducts can be nonlinear, with a plateau at higher doses; (b) cytotoxicity appears to be dose proportional; (c) compensatory hepatocyte proliferation shows NELs and can be supralinear at high doses; (d) formation of preneoplastic HAF appears to be supralinear at high doses; and (e) NELs can exist for tumor development, and the exposure response can be supralinear. We interpret these findings to reflect thresholds for hepatocellular initiating effects of these carcinogens and exaggerated responses at high exposures due to toxicity and compensatory hepatocyte proliferation. Such enhanced proliferation of hepatocytes harboring DNA damage is postulated to result in mutations that lead to supralinear initiation of carcinogenesis. Our research, therefore, permits the suggestion that linear extrapolation from high exposures to postulated low-exposure effects can yield overestimates. Such extrapolation must be supported by mechanistic research. Based on these and on other findings, we have suggested (46) that the cancer risk assessment procedures currently used for epigenetic or nongenotoxic carcinogens, which provide for a safety margin or a margin of exposure (25) , could also be applied to DNA-reactive carcinogens. We have documented for AAF and DEN, two of the most potent hepatocarcinogens, that the cellular effects in the liver are sublinear at low exposures. Importantly, no-observed-effect levels for preneoplastic lesions and promotable liver tumors have been demonstrated. This supports the likelihood of thresholds for these cellular responses in the most susceptible target organ for these carcinogens. Accordingly, NELs for requisite molecular effects such as DNA adducts, for example, may be delineated through appropriate research (22) . From this information, a carcinogen safe exposure level (SEL) can be derived, as shown in Table 8 , allowing an uncertainty factor of 10 for extrapolation to humans, which is conservative, since rodents are more susceptible (51) , and a factor 10 for individual susceptibility, due to differences in carcinogen biotransformation (11, 15) . For AAF and DEN, DNA adducts can be assumed to be necessary for carcinogenicity ( Figure 1 ) and would provide the most conservative NEL for calculating a SEL. We have not yet identified a NEL for DNA adducts, but for the subsequent step in carcinogenesis, induction of HAF, the NEL was 0.126 mmol/kg with AAF (Table 5) , and with DEN, the lowest effective level was 0.25 mmol/kg (Table 3 ). Based on other work, we have projected that the NEL is probably 0.1 mmol/kg (48) . Applying an additional UF of 10 to adjust from HAF to adducts together with the standard UFs, the SEL for both is calculated to be 0.1 j..Lmol/kg. Human safety is assured if the SEL is greater than human exposure. Humans are not exposed to AAF, a synthetic compound, and humans are exposed to only traces of DEN (14) , but the likely environmental exposure to all N-nitroso compounds and to aromatic amines is unlikely to exceed the NEL levels described here, except for the exposures of cigarette smokers, snuff users (24, 31), and individuals who consume exceptionally large quantities of foods that are rich in such compounds, such as some smoked meats and fish (32, 38) , or those exposed in occupational settings (37) . ACKNOWLEDGMENT We thank N. Rivera and K. Bateman for assistance in preparation of the manuscript.
